Literature DB >> 6704287

Severe megaloblastic anaemia associated with abnormal azathioprine metabolism.

L Lennard, M F Murphy, J L Maddocks.   

Abstract

Severe anaemia is a rare, unexplained, side effect of azathioprine therapy. We report here such a case associated with a previously unreported abnormality in azathioprine metabolism. A 57 year old man on azathioprine therapy, for a presumed collagen vascular disease, developed severe megaloblastic anaemia. This resolved on cessation of azathioprine treatment. A very high concentration of an azathioprine metabolite, 6-thioguanine nucleotide, was found in the patient's red blood cells and this was confirmed by subsequent rechallenge with a single dose of 50 mg azathioprine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6704287      PMCID: PMC1463323          DOI: 10.1111/j.1365-2125.1984.tb02333.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation.

Authors:  S N Wickramasinghe; H Dodsworth; R M Rault; B Hulme
Journal:  Transplantation       Date:  1974-11       Impact factor: 4.939

2.  Effects of azathiprine in a disorder of uric acid metabolism and cerebral function.

Authors:  W L Nyhan; L Sweetman; D G Carpenter; C H Carter; D Hoefnagel
Journal:  J Pediatr       Date:  1968-01       Impact factor: 4.406

3.  Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

Authors:  L Lennard; C A Rees; J S Lilleyman; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

4.  Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells.

Authors:  L Lennard; J L Maddocks
Journal:  J Pharm Pharmacol       Date:  1983-01       Impact factor: 3.765

  4 in total
  10 in total

1.  Peliosis hepatis induced by 6-thioguanine administration.

Authors:  D Larrey; E Fréneaux; A Berson; G Babany; C Degott; D Valla; D Pessayre; J P Benhamou
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

2.  TPMT*26 (208F-->L), a novel mutation detected in a Chinese.

Authors:  Shirley Kow Yin Kham; Chin Kok Soh; Derrick Chen Wee Aw; Allen Eng Juh Yeoh
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

3.  Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population.

Authors:  M Tinel; A Berson; D Pessayre; P Letteron; M P Cattoni; Y Horsmans; D Larrey
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

4.  Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris.

Authors:  L Lennard; C I Harrington; M Wood; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

5.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

6.  Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity.

Authors:  C N Bernstein; L Artinian; P A Anton; F Shanahan
Journal:  Dig Dis Sci       Date:  1994-08       Impact factor: 3.199

7.  TPMT in the treatment of Crohn's disease with azathioprine.

Authors:  L Lennard
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

8.  Azathioprine metabolism in kidney transplant recipients.

Authors:  L Lennard; C B Brown; M Fox; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 9.  Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: a review.

Authors:  A Anstey; L Lennard; S C Mayou; J D Kirby
Journal:  J R Soc Med       Date:  1992-12       Impact factor: 18.000

10.  miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells.

Authors:  Yoshihiro Morimoto; Tsunekazu Mizushima; Xin Wu; Daisuke Okuzaki; Yuhki Yokoyama; Akira Inoue; Tsuyoshi Hata; Haruka Hirose; Yamin Qian; Jiaqi Wang; Norikatsu Miyoshi; Hidekazu Takahashi; Naotsugu Haraguchi; Chu Matsuda; Yuichiro Doki; Masaki Mori; Hirofumi Yamamoto
Journal:  Br J Cancer       Date:  2020-02-18       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.